Kenvue Inc. $KVUE Shares Purchased by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 19.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 431,394 shares of the company’s stock after acquiring an additional 71,591 shares during the period. Cullen Frost Bankers Inc.’s holdings in Kenvue were worth $7,442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Kenvue by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after purchasing an additional 1,604,040 shares during the period. American Century Companies Inc. boosted its holdings in Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after purchasing an additional 6,781,640 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Kenvue by 13.5% during the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock valued at $375,377,000 after acquiring an additional 2,747,952 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Kenvue by 101.3% during the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after acquiring an additional 9,240,434 shares during the period. Finally, Amundi boosted its holdings in shares of Kenvue by 21.6% during the third quarter. Amundi now owns 17,645,761 shares of the company’s stock valued at $277,012,000 after acquiring an additional 3,135,871 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $17.33 on Thursday. The company has a market capitalization of $33.27 billion, a P/E ratio of 20.38, a PEG ratio of 1.30 and a beta of 0.55. The company has a 50-day simple moving average of $17.42 and a 200 day simple moving average of $17.39. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $24.35. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same period in the previous year, the business earned $0.24 earnings per share. Kenvue’s revenue for the quarter was up 4.5% compared to the same quarter last year. Sell-side analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s payout ratio is 97.65%.

Analyst Ratings Changes

Several brokerages have recently issued reports on KVUE. Barclays reduced their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Canaccord Genuity Group boosted their price target on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. UBS Group reduced their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Finally, Citigroup reduced their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $19.33.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.59% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.